Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 nov 2009 - 08:05
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Third Quarter 2009 Results
Bericht
Total revenues and other operating income increased by 15% to €94.3 million.
Operating profit of €15.5 million versus €9.6 million in Q3 2008.
Quarter-end cash and short-term liquidities of €411.9 million.
Undiluted EPS of €0.15 for the quarter.
2009 full year guidance reiterated: total revenues and other operating income expected to grow 20% in constant currencies ; operating profit for 2009 expected to improve significantly compared to 2008; strong cash position.
Leiden, the Netherlands (November 3, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the third quarter of 2009, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.
Datum laatste update: 01 september 2024